According to filings with the U.S. Securities and Exchange Commission, Nanochon is raising $3,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamin Holmes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nanochon
At present, there is an established clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, todays standard replacement joints are very invasive, and not permanent. The lifespan of common replacement joints limits their effective use in patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options. Nanochon, is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochons aim is to set a new clinical standard for cartilage restoration.

To learn more about Nanochon, visit http://www.nanochon.com/

Contact:
Benjamin Holmes, Chief Executive Officer
703-994-6099
https://www.linkedin.com/in/bbhceo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.